OVERVIEW OF THE PHARMACEUTICAL MARKET IN SERBIA
While the market is small in terms of absolute numbers, relative per capita spending on medicines is expected to improve over the long term. As the country continues its economic convergence with developed Europe, drug consumption is also expected to rise. However, financial inefficiencies within the health insurance system mean that the National Health Insurance Institution ( RZZO ) is unable to always meet its obligations on time, leaving patients to pay for formerly reimbursed medicines or hospitals having to cover the difference .
Headline Expenditure Projections
Pharmaceuticals: RSD75.70bn (US$1.03bn) in 2011 to RSD81.44bn (US$0.92bn) in 2012; +7.6% in local currency terms and -11.0% in US dollar terms.
Healthcare: RSD347.71bn (US$4.74bn) in 2011 to RSD367.32bn (US$4.14bn) in 2012; +5.6% in local currency terms and -12.6% in US dollar terms.
Medical devices: RSD16.64bn (US$223mn) in 2011 to RSD19.98bn (US$223mn) in 2012; +20.1% in local currency terms and -0.7% in US dollar terms.
Competitive Landscape
The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
While the market is small in terms of absolute numbers, relative per capita spending on medicines is expected to improve over the long term. As the country continues its economic convergence with developed Europe, drug consumption is also expected to rise. However, financial inefficiencies within the health insurance system mean that the National Health Insurance Institution ( RZZO ) is unable to always meet its obligations on time, leaving patients to pay for formerly reimbursed medicines or hospitals having to cover the difference .
Headline Expenditure Projections
Pharmaceuticals: RSD75.70bn (US$1.03bn) in 2011 to RSD81.44bn (US$0.92bn) in 2012; +7.6% in local currency terms and -11.0% in US dollar terms.
Healthcare: RSD347.71bn (US$4.74bn) in 2011 to RSD367.32bn (US$4.14bn) in 2012; +5.6% in local currency terms and -12.6% in US dollar terms.
Medical devices: RSD16.64bn (US$223mn) in 2011 to RSD19.98bn (US$223mn) in 2012; +20.1% in local currency terms and -0.7% in US dollar terms.
Competitive Landscape
The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY
SWOT ANALYSIS
Serbia Pharmaceuticals And Healthcare Industry SWOT
Serbia Political SWOT
Serbia Economic SWOT
Serbia Business Environment SWOT
PHARMACEUTICAL RISK/REWARD RATINGS
Table: Emerging Europe Regional Pharma Risk/Reward Ratings For Q113
Rewards
Risks
MARKET SUMMARY
REGULATORY REGIME
Table: The Number of Products On The Drugs List
Corruption In The Healthcare Sector
Intellectual Property Environment
Promotion
Pricing Regime
Price Developments
Reimbursement Regime
Table: Leading Suppliers Of Medicines To RZZO, By Value (RSDmn)
Table: Cost Of Prescriptions Covered By RZZO By Anatomical Therapeutic Chemical (ATC) Classification (RSD '000)
INDUSTRY DEVELOPMENTS
Epidemiology
Communicable Diseases
Non-Communicable Diseases
Healthcare Sector
Table: Major General And Specialised Hospitals
Healthcare Insurance
Healthcare Debts
Clinical Trials
Medical Devices
Table: Medical Device Classification In Serbia
INDUSTRY FORECAST SCENARIO
Overall Market Forecast
Table: Pharmaceutical Sales Indicators 2008-2016
Healthcare Market Forecast
Table: Healthcare Expenditure Indicators 2008-2016
Table: Healthcare Governmental Indicators 2008-2016
Table: Healthcare Private Indicators 2008-2016
Key Growth Factors – Macroeconomic
Table: Serbia – Economic Activity
Prescription Drug Market Forecast
Table: Prescription Drug Sales Indicators 2008-2016
Patented Drug Market Forecast
Table: Generic Drug Sales Indicators 2008-2016
© BUSINESS MONITOR INTERNATIONAL LTDPAGE
Serbia Pharmaceuticals & Healthcare Report Q1 2013
Generic Drug Market Forecast
Table: Generic Drug Sales Indicators 2008-2016
OTC Medicine Market Forecast
Table: OTC Medicine Sales Indicators 2008-2016
Pharmaceutical Trade Forecast
Table: Exports Indicators 2008-2016
Table: Imports Indicators 2008-2016
Table: Trade Balance Indicators 2008-2016
Medical Device Market Forecast
Table: Medical Devices Sales Indicators 2008-2016
Other Healthcare Data Forecasts
Key Risks To BMI’s Forecast Scenario
COMPETITIVE LANDSCAPE
Investment Climate
Pharmaceutical Industry
Table: Companies Involved In The Serbian Pharmaceutical Industry
Domestic Pharmaceutical Industry
Domestic Company Activity
Foreign Pharmaceutical Industry
Table: Proposed Members Of Serbia’s Pharmaceutical Industry Association
Foreign Company Activity
Pharmaceutical Wholesale And Retail
COMPANY MONITOR
Indigenous Company Profiles
Hemofarm (Stada)
Galenika
Zdravlje Actavis (Watson + Actavis)
Jugoremedija
Multinational Company Profiles
Pfizer
GlaxoSmithKline
Novartis
Sanofi
Merck & Co
Krka
DEMOGRAPHIC OUTLOOK
Table: Serbia's Population By Age Group, 1990-2020 ('000)
Table: Serbia's Population By Age Group, 1990-2020 (% of total)
Table: Serbia's Key Population Ratios, 1990-2020
Table: Serbia's Rural And Urban Population, 1990-2020
GLOSSARY
BMI METHODOLOGY
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Business Environment Ratings
Risk/Reward Ratings Methodology
Ratings System
Table: Pharmaceutical Business Environment Indicators
Weighting
TABLE: WEIGHTING OF COMPONENTS
SOURCES
SWOT ANALYSIS
Serbia Pharmaceuticals And Healthcare Industry SWOT
Serbia Political SWOT
Serbia Economic SWOT
Serbia Business Environment SWOT
PHARMACEUTICAL RISK/REWARD RATINGS
Table: Emerging Europe Regional Pharma Risk/Reward Ratings For Q113
Rewards
Risks
MARKET SUMMARY
REGULATORY REGIME
Table: The Number of Products On The Drugs List
Corruption In The Healthcare Sector
Intellectual Property Environment
Promotion
Pricing Regime
Price Developments
Reimbursement Regime
Table: Leading Suppliers Of Medicines To RZZO, By Value (RSDmn)
Table: Cost Of Prescriptions Covered By RZZO By Anatomical Therapeutic Chemical (ATC) Classification (RSD '000)
INDUSTRY DEVELOPMENTS
Epidemiology
Communicable Diseases
Non-Communicable Diseases
Healthcare Sector
Table: Major General And Specialised Hospitals
Healthcare Insurance
Healthcare Debts
Clinical Trials
Medical Devices
Table: Medical Device Classification In Serbia
INDUSTRY FORECAST SCENARIO
Overall Market Forecast
Table: Pharmaceutical Sales Indicators 2008-2016
Healthcare Market Forecast
Table: Healthcare Expenditure Indicators 2008-2016
Table: Healthcare Governmental Indicators 2008-2016
Table: Healthcare Private Indicators 2008-2016
Key Growth Factors – Macroeconomic
Table: Serbia – Economic Activity
Prescription Drug Market Forecast
Table: Prescription Drug Sales Indicators 2008-2016
Patented Drug Market Forecast
Table: Generic Drug Sales Indicators 2008-2016
© BUSINESS MONITOR INTERNATIONAL LTDPAGE
Serbia Pharmaceuticals & Healthcare Report Q1 2013
Generic Drug Market Forecast
Table: Generic Drug Sales Indicators 2008-2016
OTC Medicine Market Forecast
Table: OTC Medicine Sales Indicators 2008-2016
Pharmaceutical Trade Forecast
Table: Exports Indicators 2008-2016
Table: Imports Indicators 2008-2016
Table: Trade Balance Indicators 2008-2016
Medical Device Market Forecast
Table: Medical Devices Sales Indicators 2008-2016
Other Healthcare Data Forecasts
Key Risks To BMI’s Forecast Scenario
COMPETITIVE LANDSCAPE
Investment Climate
Pharmaceutical Industry
Table: Companies Involved In The Serbian Pharmaceutical Industry
Domestic Pharmaceutical Industry
Domestic Company Activity
Foreign Pharmaceutical Industry
Table: Proposed Members Of Serbia’s Pharmaceutical Industry Association
Foreign Company Activity
Pharmaceutical Wholesale And Retail
COMPANY MONITOR
Indigenous Company Profiles
Hemofarm (Stada)
Galenika
Zdravlje Actavis (Watson + Actavis)
Jugoremedija
Multinational Company Profiles
Pfizer
GlaxoSmithKline
Novartis
Sanofi
Merck & Co
Krka
DEMOGRAPHIC OUTLOOK
Table: Serbia's Population By Age Group, 1990-2020 ('000)
Table: Serbia's Population By Age Group, 1990-2020 (% of total)
Table: Serbia's Key Population Ratios, 1990-2020
Table: Serbia's Rural And Urban Population, 1990-2020
GLOSSARY
BMI METHODOLOGY
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Business Environment Ratings
Risk/Reward Ratings Methodology
Ratings System
Table: Pharmaceutical Business Environment Indicators
Weighting
TABLE: WEIGHTING OF COMPONENTS
SOURCES